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Abstract
Background: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus),
was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and
internationally led the World Health Organization to declare a Public Health Emergency of International Concern on
30th January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild
upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals
of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory
effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and
in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the
efficacy and safety of remdesivir in adult patients with severe COVID-19.
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Methods: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial.
Adults (≥ 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and
radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered
remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28),
defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two
categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from
hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events
required has been observed.
Discussion: This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan,
Hubei Province, China on 6th February 2020.
Trial registration: ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020.
Keywords: COVID-19, Clinical trial, Remdesivir, Antiviral, China , Administrative information
Introduction
Background and rationale {6a}
In December 2019, Wuhan City, Hubei Province experi-
enced an outbreak of pneumonia of unknown cause. On
7th January 2020, a previously unidentified betacorona-
virus, later named SARS-CoV-2 virus (or the disease
named COVID-19), was identified by the Chinese Center
for Disease Control and Prevention (China CDC) as the
aetiological agent [1]. The SARS-CoV-2 probably derived
originally from bats, and amongst coronaviruses known
to infect humans, is most closely related to, but distinct
from, the SARS coronavirus. The clinical manifestations
of COVID-19 virus infection include asymptomatic in-
fection, mild upper respiratory symptoms, severe viral
pneumonia with respiratory failure, and even death. Al-
though the risk of severe illness is not yet clear, hos-
pitals in areas with significant community
transmission have experienced a major increase in the
number of hospitalized pneumonia patients, with the
frequency of severe disease in hospitalized patients
being as high as 30% [2–4]. The progression from
prodromes (usually fever, fatigue, and cough) to se-
vere pneumonia requiring oxygen support, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO) is most commonly seen in the second week
following onset of symptoms of a viral infection [2].
The kinetics of viral replication in the respiratory
tract has not been well characterized, but this rela-
tively slow progression provides a potential time win-
dow and opportunity for antiviral therapies to
influence the course of the disease.
Remdesivir (GS-5734) is a monophosphoramidate pro-
drug of an adenosine analogue (GS-441524) and has
broad action against a range of RNA viruses [5]. It has
been identified as the most promising therapeutic agent
for evaluation in the treatment of COVID-19 by an ex-
pert committee convened by the WHO R&D Blueprint
[6]. The primary mechanism of action is the intracellular
incorporation of the pharmacologically active nucleoside
triphosphate form into nascent RNA chains by the viral
RNA-dependent RNA polymerase, causing premature
RNA chain termination [7–9]. In vitro experiments have
shown that remdesivir inhibits bat coronaviruses, en-
demic human coronavirus (OC43, 229E), and the human
pathogenic coronaviruses MERS-CoV, SARS-CoV, and
COVID-19 [10–13]. Remdesivir has shown preventive
and therapeutic effects in a mouse model of SARS-CoV
[10]. In a MERS-CoV mouse model, prophylactic and
therapeutic administration of remdesivir improved lung
function, decreased lung viral load, and reduced severe
lung pathological findings [14]. Remdesivir has also
shown prophylactic efficacy in MERS-CoV-infected In-
dian rhesus monkeys (personal communication: Gilead
Sciences, Inc.).
Evaluation of intravenously administered remdesivir
tolerance and safety in 94 healthy adult volunteers
has found it to be generally well tolerated and to
have an acceptable safety profile. The only significant
adverse effects were transient grade 1 or grade 2 in-
creases in aspartate transaminase (AST) and alanine
transaminase (ALT) (personal communication: Gilead
Sciences, Inc.). Further clinical experience was
obtained through a randomized controlled trial in
patients with Ebola virus disease. In this trial 175
patients received intravenous remdesivir with a load-
ing dose on day 1 (200 mg in adults, and adjusted for
body weight in pediatric patients), followed by a daily
maintenance dose (100 mg in adults) starting on day
2 and continuing for 9 to 13 days. The only reported
serious adverse event (SAE) was that of one patient
who experienced hypotension that resulted in cessa-
tion of the remdesivir loading dose, followed rapidly
by cardiac arrest. However, the cause of death could
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not be distinguished from the patient’s underlying se-
vere Ebola virus disease [15].
Given the in vitro and in vivo effectiveness of remdesi-
vir against a range of pathogenic human coronaviruses
and the acceptable tolerance and safety in humans, we
developed this trial with the objective of evaluating the
safety and efficacy of intravenous remdesivir in adults
with severe COVID-19.
Objectives {7}
The trial objective is to evaluate the efficacy and safety
of intravenous remdesivir combined with standard of
care compared with standard care alone in adult patients
with severe COVID-19.
Trial design {8}
This is a phase 3, parallel group, randomized, double-
blind, placebo-controlled, superiority, multicentre trial.
The allocation ratio is 2:1 in favour of remdesivir to
maximize learning about the experimental treatment
whilst allowing a wider pool of patients access to the
experimental treatment in order to support
recruitment.
Methods: participants, interventions, and
outcomes
Study setting {9}
The setting involved hospitals in Wuhan city, Hubei
Province, People’s Republic of China. Study sites in-
cluded Jin Yin-tan Hospital, Tongji Hospital, Tongji
Medical College of Huazhong University of Science &
Technology, Wuhan Lung Hospital, the Central
Hospital of Wuhan, Zhongnan Hospital of Wuhan
University, Renmin Hospital of Wuhan University,
Union Hospital, Tongji Medical College of Huazhong
University of Science & Technology, Wuhan First
Hospital, Wuhan Third Hospital, and Wuhan Fourth
Hospital.
Eligibility criteria {10}
Inclusion criteriaThe inclusion criteria are as follows:
1. Age ≥ 18 years at time of signing of informed
consent form
2. Laboratory (reverse transcription polymerase chain
reaction [RT-PCR])-confirmed COVID-19
3. Pneumonia confirmed with chest imaging
4. Hospitalized with SPO2 ≤ 94% on room air or
PaO2/FiO2 ≤ 300 mmHg
5. ≤ 12 days since symptoms onset
6. Willingness of study participant to accept
randomization to any assigned treatment arm
7. Males and females of child-bearing age must agree
to use effective birth control measures (hormone
method, barrier method, or abstinence) during the
trial and at least 7 days after the last medication
dose
8. Must agree not to enrol in any other study of an
antiviral agent prior to completing the 28-day
follow-up.
Exclusion criteriaThe exclusion criteria are as follows:
1. Physician makes a decision that trial involvement is
not in patient’s best interest, or patient has any
condition that does not allow the protocol to be
followed safely
2. Known severe liver disease (e.g. cirrhosis, ALT > 5
× upper limit of normal (ULN), or AST > 5 × ULN)
3. Patients who are pregnant or breastfeeding, or
positive pregnancy test in women of childbearing
age
4. Patients with known severe renal impairment
(estimated glomerular filtration rate ≤ 30 ml/min/
1.73 m2), or patients receiving continuous renal
replacement therapy, haemodialysis, or peritoneal
dialysis
5. Will be transferred to any other hospital which is
not a study site within 72 h
6. Receipt of any investigational treatment for
COVID-19 within 30 days prior to screening.
Who will take informed consent? {26a}
Informed consent will be obtained from eligible patients
or their substitute decision-makers (for patients lacking
decision-making capacity) by study physicians or other
trial staff with delegated responsibility.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
The consent form includes provisions for research data
and samples and residual clinical blood samples to be
stored for future scientific research on COVID-19.
Interventions
Explanation for the choice of comparators {6b}
The active arm is intravenously administered remdesivir
in addition to routine supportive care. Remdesivir was
chosen for evaluation because of its in vitro activity
against SARS-CoV, MERS-CoV, and SARS-CoV-2, and
its in vitro activity against SARS-CoV and MERS-CoV.
There are safety data for remdesivir in healthy human
volunteers and individuals with Ebola virus disease.
These data suggest that remdesivir is generally well tol-
erated and has an acceptable safety profile. It has been
identified as the most promising therapeutic agent for
treatment of COVID-19 by the WHO R&D Blueprint
[6]. The dose of remdesivir was selected on the
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recommendation of Gilead Sciences, Inc., based on
known pharmacokinetics and dose-ranging studies in
healthy volunteers. The control arm is placebo in
addition to routine supportive care. There are no proven
antiviral therapies for SARS-CoV-2 to include as an ac-
tive control comparator.
Intervention description {11a}
The intervention is described as follows for the
experimental and control groups:
1. Group A (experimental group)
(a) Loading dose: Remdesivir 200 mg in 350 ml
normal saline (0.9% sodium chloride) single
daily dose infused intravenously over
approximately 30–60 min (with a target time of
30 min) for 1 day
(b) Maintenance dose: Remdesivir 100 mg in 250
ml normal saline (0.9% sodium chloride) single
daily dose infused intravenously over
approximately 30–60 min (with a target time of
30 min) for 9 days.
2. Group B (control group)
(a) Loading dose: Placebo in 350 ml normal saline
(0.9% sodium chloride) single daily dose infused
intravenously over approximately 30–60 min
(with a target time of 30 min) for 1 day
(b) Maintenance dose: Placebo in 250 ml normal
saline (0.9% sodium chloride) single daily dose
infused intravenously over approximately 30–60
min (with a target time of 30 min) for 9 days.
Criteria for discontinuing or modifying allocated
interventions {11b}
The discontinuation/modification criteria are as follows:
1. Any serious or intolerable adverse event (AE)
which, in the investigators’ judgement, requires
withdrawal of the subject from the study. This may
include drug intolerance or an unacceptable AE;
any severe grade 4 AE, regardless of whether the
AE is considered likely related to the study drug or
not; significant results of laboratory tests which may
require withdrawal of the participant, at the
discretion of the researchers and the clinician;
allergic reactions (including oropharyngeal oedema,
severe rash, bronchospasm, and immediate-type al-
lergic reactions); acute hepatitis;1 stage III or above
acute kidney injury
2. Investigator request for the subject to be withdrawn
from the study.
Strategies to improve adherence to interventions {11c}
This item is not applicable, since active agent and
placebo are administrated intravenously by healthcare
professionals.
Relevant concomitant care permitted or prohibited
during the trial {11d}
This study seeks to evaluate the effect of remdesivir in
addition to standard of care alone, rather than an effect
that might be altered by other experimental treatments.
Therefore, all concomitant care and interventions are
permitted other than concomitant receipt of any other
experimental treatment.
Provisions for post-trial care {30}
No special arrangements for post-trial care are
anticipated.
Outcomes {12}
Primary outcome measure
The primary outcome measure is time to clinical im-
provement (TTCI) (censored at day 28).
TTCI is defined as the time (in days) from
randomization of study treatment (active or placebo)
until a decline of two categories on a six-category or-
dinal scale of clinical status (1 = hospital discharge; 2 =
hospitalization, not requiring supplemental oxygen; 3 =
hospitalization, requiring supplemental oxygen (but not
non-invasive mechanical ventilation [NIV]/high-flow
nasal cannula [HFNC] therapy); 4 = hospitalization, re-
quiring NIV and/or HFNC therapy; 5 = hospitalization,
requiring ECMO and/or invasive mechanical ventilation
[IMV]; 6 = death) or live hospital discharge, whichever
comes first.
Secondary outcome measures:The secondary outcome
measures are the following:
1. Percentage of subjects in each clinical category on
the six-category ordinal scale (time frame: days 7,
14, 21, and 28)
2. Time to disease improvement, defined as the time
to hospital discharge, or NEWS2 (National Early
Warning Score 2) of ≤ 2 maintained for 24 h (time
frame: up to 28 days)
1Acute hepatitis is defined by the following: (1i) Development of ALT
≥ 3 × upper limit of normal (ULN) and bilirubin ≥ 2 × ULN(> 35%
conjugated bilirubin). If conjugated/unconjugated bilirubin is not
available, urobilinogen should be tested for on a test strip, and a
positive result to be indicative of > 35% conjugated bilirubin. If neither
tests isare available, the study drug should be discontinued. (2ii) ALT
≥ 5 × ULN. (3iii) ALT ≥ 3 × ULN and onset of symptoms of hepatitis,
such as fatigue, nausea, vomiting, right upper quadrant pain, fever,
rash, or eosinophilia.
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3. All-cause mortality (time frame: up to 28 days)
4. Duration (days) of IMV (time frame: up to 28 days)
5. Duration (days) of supplemental oxygenation (time
frame: up to 28 days)
6. Length of hospital stay (days) (time frame: up to 28
days)
7. Incidence of nosocomial secondary infection
8. Time to SARS-CoV-2 virus RT-PCR negativity in
upper and lower respiratory tract specimens (time
frame: up to 28 days)
9. Change (reduction) in SARS-CoV02 viral RNA load
in upper and lower respiratory tract specimens as
assessed by area under viral load curve (time frame:
up to 28 days)
10. Pharmacokinetic parameters of remdesivir or its
active metabolites
11. Frequency of SAEs (time frame: up to 28 days).
Participant timeline {13}
Table 1 shows the timeline of participant assessments/
interventions.
Sample size {14}
The primary outcome is TTCI (censored at day 28).
An interim analysis for futility and efficacy is planned
at the midpoint of the trial. At this point the sample
size may also be re-assessed. A one-sided type I error
of 2.5% across the two stages of the trial and a power
of 80% if the hazard ratio comparing remdesivir to
placebo is 1.4 is used. This hazard ratio corresponds
to a reduction in TTCI to 15 days on remdesivir if
the TTCI on standard of care was 21 days. Triangular
boundaries [16] are used to account for the multiple
looks at the data, and allowance for the 2:1
randomization in favour of remdesivir is made. Under
these assumptions, the total number of events re-
quired in this study is 325.
Assuming an 80% event rate within 28 days across
both arms and a dropout rate of 10% implies that ap-
proximately 453 patients are to be recruited for this trial
(151 on placebo and 302 on remdesivir).
Recruitment {15}
Patients will be recruited from the designated hospitals
for patients with COVID-19 virus.
Assignment of interventions: allocation
Sequence generation {16a}
A permuted block (30 patients per block) randomization
sequence, including stratification, is prepared by a statis-
tician not involved in the trial using SAS software, ver-
sion 9.4 (SAS Institute). Patient randomization is
stratified based on respiratory support methods at the
time of enrolment: (1) no oxygen support, oxygen
support with nasal duct or mask; (2) high-flow oxygen,
NIV, IMV/ECMO.
Concealment mechanism {16b}
Eligible patients were allocated to receive medication in
individually numbered packs according to the sequential
order provided by the randomization centre (Jin Yin-tan
Hospital central pharmacy). Remdesivir and placebo are
pre-blinded and stored in a secure area in the pharmacy
at a temperature strictly controlled according to the
protocol. An independent pharmacist is assigned to dis-
pense the study drug in waterproof, sealed, opaque bags.
Implementation {16c}
Patients will receive medication in individually num-
bered packs according to the sequential order provided
by the randomization centre. Opaque envelopes were
provided for emergency unblinding events. The alloca-
tion sequence was generated by the institutes of Materia
Medica, Chinese Academy of Medical Sciences & Peking
Union Medical College. Participants are enrolled by the
investigators of each study site. A pharmacist in the cen-
tral pharmacy assigns participants to interventions.
Assignment of interventions: blinding
Who will be blinded? {17a}
This is a double-blind trial. Trial participants, investiga-
tors, care providers, outcome assessors, and data analysts
are all blinded. Treatment allocation will only be un-
blinded after database lock.
Procedure for unblinding if needed {17b}
Unblinding is permissible when investigators believe that
there is a very strong need to know the study drug allo-
cation in order to perform any agent treatment/action.
Whenever possible, unblinding will only be conducted
after discussion with the study principal investigator.
The procedure for revealing a participant’s allocated
intervention is as follows: (1) investigators confirm that
the patient meets the criteria of unblinding according to
the protocol; (2) the independent pharmacist opens the
sealed envelope and informs the investigators of the allo-
cation; (3) information about the date, time, and reason
of unblinding will be recorded in the electronic data cap-
ture (EDC) system and the envelope; (4) the envelope
must be sealed again as soon as possible and securely
stored along with the primary files of the subject.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Investigators are responsible for assessment and collec-
tion of outcome, baseline, and other trial data, and the
data are double checked by the clinical research coordi-
nators and clinical research associates as well as data
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managers. Nasopharyngeal/oropharyngeal swabs, lower
respiratory tract specimens (sputum/tracheal aspirate/
bronchial alveolar lavage fluid), feces/anal swabs, and
pharmacokinetic samples (whole blood) will be sent to a
central laboratory, where tests will performed according
to laboratory standard operating procedures (SOPs).
Data collection forms can be found at https://edc.clin-
flash.net/login.
For the efficacy outcome measures, two scales (six-cat-
egory ordinal scale of clinical status and NEWS2) are
used. Investigators will be trained to use these scales.
Plans to promote participant retention and complete
follow-up {18b}
Subjects may voluntarily withdraw from the trial at
any time. This decision must be communicated with
Table 1 Study timeline of participant assessments/interventions
Process Screening/baseline/
randomization
Treatment phase Follow-up
phase
B/L/D0 D1–D10 D14
±1
D21
±3
D28
±3
Inclusion/exclusion criteria X
Written informed consent X
Demographics X
Assessment of concomitant chronic diseases X
Efficacy/safety assessment
ECG X X
Chest imaging X X (only on D10) X
Vital signs
(body temperature, heart rate, blood pressure, breathing rate,
oxygen saturation, etc.)
X X X X X
Clinical symptoms assessment
(fever, cough, diarrhea, dyspnea)
X X X X X
Primary endpoint assessment X X X X X
Adverse events X X X X X
Laboratory test
Diagnosis
(clinical diagnosis, antibody diagnosis, or pathogen diagnosis)
X
Whole blood count
(sampling time)
X X (only on D3, D7, and D10)
Coagulation routine
(sampling time)
X X (only on D3, D7, and D10)
Kidney and liver function tests
(sampling time)
X X (only on D3, D7, and D10)
Arterial blood gas analysis X
Pregnancy test
(urine/blood, for women of childbearing age only)
X
Nasopharyngeal/ oropharyngeal swab X X X X X
Lower respiratory tract specimen
(sputum/tracheal aspirate/bronchial alveolar lavage fluid) if
available
X X X X X
Feces/anal swabs X X X X X
Pharmacokinetic sampling
(approximately 4 ml whole blood)
X (only on D1, D3, D7 [as needed],
and D10)
Interventions
Remdesivir/placebo X
Concomitant medications
(record only)
X X X X X
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and reviewed by investigators. Staff at study sites
should explain to these subjects the importance of
staying in the study for the full duration of follow-up
of this trial. For any withdrawal from this trial, inves-
tigators must fill in the withdrawal reason in the
electronic case report form (eCRF) and try to
complete all remaining assessments up to day 28 after
randomization. For subjects who withdraw due to
AEs, investigators should closely follow up their AEs
until the AEs disappear, return to the baseline state,
or the AE condition is stable. If subjects are lost to
follow-up, existing data collected up until the time of
loss to follow-up will be used.
Investigators may request for subjects to be withdrawn
from receiving the study drugs for clinical or other rea-
sons. In this case, subjects should remain in the trial after
terminating the trial treatment and be followed up for all
scheduled visits and the corresponding data recorded.
Data management {19}
The EDC system will be used for data management,
including data entry, query, coding, security, and stor-
age. The data manager built the database according
to the protocol, and at the same time made logical
verification settings for data validity, so as to verify
the data. The data of each enrolled subject (including
discontinued subjects) will be recorded into the data-
base/eCRF rapidly, completely, and accurately. Each
completed eCRF will be reviewed and signed (elec-
tronically) by the investigators. The data manager will
check the data and ask investigators to resolve any
queries identified. The data administrator will proof-
read and modify the data according to investigators’
answers. The data are securely stored in the EDC
system, with the server located in Zhejiang Province,
China.
Confidentiality {27}
Subjects’ data collected in CRFs will be identified by
a study subject ID only. Samples collected through
the study will also be identified by a study subject ID
only. The log linking the study subject ID with the
patient identifying information will be held at each
recruitment site. In the emergent or rare event that,
for safety or regulatory reasons, it may be necessary
to identify a subject, the sponsor and investigators
were bound to keep this information confidential.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Nasopharyngeal/oropharyngeal swabs, lower respiratory
tract specimens (sputum/tracheal aspirate/bronchial
alveolar lavage fluid), feces/anal swabs, and pharmacoki-
netic samples (whole blood) will collected by investiga-
tors or designees, marked with the study subject ID, and
then immediately sent to the central laboratory for cor-
onavirus nucleic acid detection or remdesivir/active me-
tabolites concentration detection. Sample collection,
handling, labelling, storage, shipping, processing, etc. will
be performed according to the requirements of the oper-
ation manual in the central laboratory, Teddy Clinical
Research Laboratory (Shanghai) Ltd.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
The primary outcome is TTCI up to day 28 of patients
on remdesivir compared to patients receiving placebo.
Patients will be randomized at a ratio of 2:1 to receive
either remdesivir or placebo. All reporting will adhere to
the Consolidated Standards of Reporting Trials (CON-
SORT) guideline as well as the corresponding extension
for adaptive clinical trials [17, 18].
The final analysis of the primary endpoint will use a
Cox proportional hazards model following the intention-
to-treat principle. The final analysis will be conducted
once a total of 325 events have occurred across both
treatment groups. Under the assumption of an 80%
event rate within 28 days and accounting for 10% drop-
out, this means that the maximum number of patients
to be recruited is approximately 453. A standardized test
statistic is then found on the basis of this model—if this
test statistic exceeds 2.095, then it will be concluded that
remdesivir is significantly better than placebo. Median
unbiased effect estimates and confidence intervals ac-
counting for the interim analysis will be reported [19].
Analysis of secondary endpoints will use a logistic model
for binary variables such as mortality and a Cox propor-
tional hazards model for time-to-event endpoints. A
statistical analysis plan (SAP) providing all details of the
analyses to be undertaken will be completed before any
data analysis will be conducted.
3.18.2. Interim analyses {21b}
An interim analysis for efficacy and lack of benefit will
be undertaken once a total of 163 events have been ob-
served across all treatment group. For the interim ana-
lysis the primary endpoint will be analysed using a Cox
proportional hazards model using the intention-to-treat
principle. A standardized test statistic is then found on
the basis of this model and if this test statistic falls below
0.741, the trial will be stopped for lack of benefit of
remdesivir. If the test statistic exceeds 2.222, the trial
will terminate with the conclusion, that remdesivir is sig-
nificantly better than control. If the test statistics falls
between 0.741 and 2.222, the trial continues to the
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second stage and a sample size re-estimation on the
basis of the observed event rate will take place. The in-
terim analysis is to be conducted by an independent
statistician and reviewed by the DSMC. Should the trial
stop for futility or efficacy the median unbiased estimate
as well as confidence intervals accounting for the interim
analysis will be reported [19].
3.18.3. Methods for additional analyses (e.g. subgroup
analyses) {20b}
Separate supporting analysis will be undertaken for gen-
der and age groups (<60 and over 60 years of age at
randomization). These analyses will use a Cox propor-
tional hazards model of the primary endpoint. Addition-
ally, mortality will be analysed for each of these
subgroups using a logistic regression model.
3.18.4. Methods in analysis to handle protocol non-
adherence and any statistical methods to handle missing
data {20c}
Multiple imputation will be used for missing data. The
primary analysis will use the intention-to-treat principle
and a per protocol analysis will be undertaken to assess
the robustness of the findings.
3.18.5. Plans to give access to the full protocol,
participant-level data, and statistical code {31c}
These plans are not yet in place.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
3.19.1.1. Coordinating centre The study is led by the
China-Japan Friendship Hospital, Wuhan Jin Yin-tan
Hospital, Wuhan Central Hospital, Huazhong University
of Science & Technology Tongji Hospital, Wuhan Uni-
versity Zhongnan Hospital, Wuhan Pulmonary Hospital,
Wuhan University People's Hospital, Wuhan Union
Hospital, and other hospitals.
3.19.1.2. Trial steering committee
The trial steering committee consists of the following
members:
 Chen Wang, President of Peking Union Medical
College
 Bin Cao (China-Japan Friendship Hospital), deputy
team leader of Novel Coronavirus Pneumonia (NCP)
Group
 Dingyu Zhang (Jin Yin-tan Hospital), Director of
NCP Designated Hospital.
 Ke Wang, Director of Institute of Medicine, Chinese
Academy of Medical Sciences.
Trial operation committee
The trial operation committee consists of Yeming Wang
and Fei Zhou of China-Japan Friendship Hospital, and
Ying Liu, Shunan Ruan, and Wen Liu of Jin Yin-tan
Hospital.
Trial monitoring
Trial monitoring is performed by Hangzhou Tigermed
Consulting Co., Ltd.
Data management team
The data management team is Hangzhou Tigermed
Consulting Co., Ltd.
Clinical research organization
The clinical research organization is Hangzhou
Tigermed Consulting Co., Ltd.
Composition of the data monitoring committee, its role
and reporting structure {21a}
The independent Data Safety Monitoring Board (DSMB)
in this study is responsible for reviewing the reports re-
garding the safety of the study patients and protocol ad-
herence and making recommendations to continue or
terminate the study or modify sample size on the basis
of the results from the interim analysis. The DSMB
members are all independent of the sponsor and have
no financial or other conflicts of interest.
Data monitoring committee (DMC) members
Table 2 lists the DMC members.
Adverse event reporting and harms {22}
AEs and SAEs will be collected from the time of in-
formed consent to day 28. SAEs occurring after day
28 ± 3 will be reported if investigators determine that
these SAEs are related to the study drugs. SAEs will be
followed up until the SAE has subsided, returned to
baseline, or is stable.
Investigators or designees are responsible for collect-
ing, assessing, reporting, and managing AEs. AEs will be
fully investigated and recorded in detail in the CRF, in-
cluding onset date, the duration of AE, symptoms/signs,
severity, action taken to manage the AE, relationship
with the study drug, outcome of the AE, and date of out-
come assessment (if outcome was other than recovering,
not recovered, or unknown).
Frequency and plans for auditing trial conduct {23}
The contract research organization (Hangzhou
Tigermed Consulting Co., Ltd.) will be responsible for
monitoring the trial. On-site monitoring and remote
monitoring visits will be conducted in accordance with
the study monitoring plan to ensure the completeness
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and accuracy of research data. Audits may be conducted
at any time during or after the study.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
During the trial, the principal investigator will inform
the Independent Ethics Committee (IEC) of any revision
or modification of the protocol. The revision or modifi-
cation will only be implemented after receiving IEC ap-
proval, unless it is necessary to be implemented in order
to eliminate immediate and direct harm to patients, in
which case the IEC will be informed as soon as possible.
After any protocol amendment, the informed consent
form and any other written information provided to sub-
jects will be updated as necessary. Investigators will in-
form subjects in time and ask them to sign the revised
informed consent form to confirm their participation.
The updated informed consent form must be approved
by the IEC before implementation.
Dissemination plans {31a}
We will communicate trial results to national and inter-
national health authorities, healthcare professionals, the
public, and other relevant groups as soon as the trial re-
sults are available.
Discussion
This study is the first double-blind, placebo-controlled
trial of an experimental therapeutic for COVID-19.
Whilst the COVID-19 epidemic has been declared a
public health emergency of international concern, this
does not negate the need to generate robust evidence in
which healthcare professionals, patients, their families,
and public health authorities can have confidence. In
past epidemics, unproven treatments have been used on
a compassionate use basis, in observational studies, or in
underpowered trials, and the results are uncertainty and
ongoing treatment dilemmas. Randomized, placebo-
controlled trials are well established as the best way to
minimize bias and confounding and produce reliable evi-
dence. Such trials can be implemented even in the most
difficult circumstances; in fact, the difficult circum-
stances themselves make it even more important that
patient care is not driven by fear and rumour but by sci-
ence and evidence. During health emergencies, doctors
and politicians are under enormous pressure to find
cures to save lives and stop the epidemic, whilst patients
are willing to try anything in the face of a frightening
and unknown threat. We must resist these pressures and
make sure that patients benefit from the fruits of sci-
ence, even in difficult times.
The use of placebo is especially beneficial in the midst
of great anxiety, when the pressures to announce a cure
or act on preliminary, but inconclusive data, are intense.
A placebo relieves the temptation from all involved in
the trial to engage in speculation and the worry that they
are withholding what early (but often false) impressions
may suggest is a promising drug. Whilst remdesivir has
shown promising activity in preclinical models of severe
CoV infection, it is currently unknown whether it will
prove safe and effective in treating severe COVID-19,
both because of its uncertain antiviral efficacy and the
unclear importance of ongoing viral replication versus
an inflammatory process in disease pathogenesis in se-
verely ill patients. Of note, remdesivir yielded positive
results in preclinical models of Ebola virus infection but
was inferior to two monoclonal antibody therapies in
treated patients [15].
During epidemics, as well as calls to treat every-
one, other voices demand that vulnerable patients
not be treated as ‘guinea pigs’. Clinical trials use
well-deliberated, tested, and transparent scientific
methods, and are undertaken as a joint endeavour
between patients and health professionals within a
clear ethical framework. Health emergencies raise
additional ethical concerns, but these have been
carefully considered by various groups, and clear
guidance exists on the conduct of clinical research
during health emergencies [20–22].
The choice of the primary endpoint for a clinical trial
is always challenging, but it has added difficulties when
dealing with a disease with uncertain natural history, an
overstretched workforce, and the desire for an early
Table 2 Data monitoring committee members
Name Role Position
Jieming Qu Chair Professor of Respiratory Medicine & President, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Weichung Joe
Shih
Member Director of Biometrics Division of the Cancer Institute of New Jersey, Rutgers University
Rob Fowler Member Senior scientist, Evaluative Clinical Sciences, Trauma, Emergency & Critical Care Research Program, Sunnybrook Research
Institute, Toronto, Canada
Rory Collins Member Head, Nuffield Department of Population Health, University of Oxford, UK
Chen Yao Member Biometrics Division of Peking University
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answer. This requires an endpoint that is clinically
meaningful, is based on simple data collection, has suf-
ficient power, and will occur early. It also requires stat-
istical methods that are robust to misspecification of
design parameters, such as the endpoint frequency. We
believe that our primary endpoint is both pragmatic
and informative, but we have included a range of sec-
ondary endpoints to show consistency with the primary
endpoint, as recommended by the US Food and Drug
Administration for trials in influenza [23].
Trial status
The protocol version is number 3.0, dated 9th February
2020.
The first patient, first visit was on 6th February 2020; the
recruitment end date was anticipated to be 3rd April 2020.
Acknowledgements
We acknowledge assistance from many sources. Gilead Sciences, Inc.
provided previous preclinical and clinical data, and provided and shipped
remdesivir and placebo free of charge.
WHO Novel Coronavirus R&D provided suggestions. Teddy Clinical Research
Laboratory (Shanghai) Co., Ltd. will act as the central laboratory. The RT-PCR
instrument and assay was provided by Roche. Site management organization
(SMO) assistance was provided by Shanghai MedKey Med-Tech Development
Co., Ltd., Clinplus Co., Ltd., Hangzhou Simo Co., Ltd., and Medpison Co., Ltd.
Daniel Pan, Ni Li, Yinyan Xu, Zinan Yin, Jianwei Cui, Yindong Zhang, Zhiyan
Xu, and Wang assisted with the translation from Mandarin to English.
Administrative information
Note: The numbers in square brackets in this protocol refer to SPIRIT
checklist item numbers. The order of the items has been modified to group
similar items (see http://www.equator-network.org/reporting-guidelines/
spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).
Title {1} A Phase 3 Randomized, Double-blind,
Placebo-controlled, Multicentre Study to
Evaluate the Efficacy and Safety of Intra-
venous Remdesivir in Adult Patients With
Severe Pneumonia caused by COVID-19
virus Infection
Trial registration
{2a and 2b}
ClinicalTrials.gov
NCT04257656
Protocol version {3} Version 3.0
09 February 2020
Funding {4} Funded by:
• Emergency project for novel coronavirus
pneumonia of the Ministry of Science and
Technology (2020YFC0841300)
• Chinese Academy of Medical Sciences
(CAMS) Innovation Fund for Medical
Sciences (CIFMS 2018-I2M-1-003)
• National Science Grant for Distinguished
Young Scholars (81425001/H0104)
• The National Key Research and
Development Program of China
(2018YFC1200102)
• The Beijing Science and Technology
Project (Z19110700660000)
• National Mega-projects for Infectious Dis-
eases in China (2017ZX10103004 and
2018ZX10305409).
Other support:
(Continued)
• China Evergrande Group, Jack Ma
Foundation, Sino Biopharmaceutical
Limited, Ping An Insurance (Group), New
Sunshine Charity Foundation, International
Severe Acute Respiratory and emerging
Infections Consortium (ISARIC)
• NIHR Senior Research Fellowship (TJ:
2015-08-001)
Author details {5a} Department of Pulmonary and Critical
Care Medicine, Center of Respiratory
Medicine, National Clinical Research
Center for Respiratory Diseases, China-
Japan Friendship Hospital, Beijing, China
Jin Yin-tan Hospital, Wuhan, Hubei Prov-
ince, China;
Tongji Hospital, Tongji Medical College of
Huazhong University of Science &
Technology, Wuhan, Hubei Province,
China;
Wuhan Lung Hospital, Wuhan, Hubei
Province, China;
The Central Hospital of Wuhan, Wuhan,
Hubei Province, China;
Zhongnan Hospital of Wuhan University,
Wuhan, Hubei Province, China;
Renmin Hospital of Wuhan University,
Wuhan, Hubei Province, China;
Union Hospital, Tongji Medical College of
Huazhong University of Science &
Technology, Wuhan, Hubei Province,
China;
Wuhan First Hospital, Wuhan, Hubei
Province, China;
Wuhan Third Hospital, Wuhan, Hubei
Province, China;
Wuhan Fourth Hospital, Wuhan, Hubei
Province, China;
Institute of Respiratory Medicine, Chinese
Academy of Medical Sciences, Beijing,
China;
Institute of Clinical Medical Sciences,
China-Japan Friendship Hospital, Beijing,
China;
Lancaster University, Lancaster, UK;
University of Virginia School of Medicine,
Charlottesville, VA, USA;
University of Oxford, Oxford, UK;
Peking Union Medical College, Beijing,
China
Name and contact information
for the trial sponsor {5b}
China-Japan Friendship Hospital, Beijing,
People’s Republic of China
Role of sponsor {5c} The study sponsor and funders had no
role in study design; collection,
management, analysis, or interpretation of
data; writing of the report; or the decision
to submit the report for publication
Authors’ contributions {31b}
BC, YW, GHF, FZ, FH, and PWH designed the trial. TJ and GHF developed the
statistical analysis plan. All authors read and approved the final manuscript.
Funding {4}
Funding was provided by the following:
• Emergency project for novel coronavirus pneumonia of the Ministry of
Science and Technology (2020YFC0841300)
Wang et al. Trials          (2020) 21:422 Page 10 of 11
• Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical
Sciences (CIFMS 2018-I2M-1-003)
• National Science Grant for Distinguished Young Scholars (81425001/H0104)
• The National Key Research and Development Program of China
(2018YFC1200102)
• The Beijing Science and Technology Project (Z19110700660000)
• National Mega-projects for Infectious Diseases in China (2017ZX10103004
and 2018ZX10305409)
• TJ is funded by a National Institute for Health Research (NIHR) Senior
Research Fellowship (2015-08-001)
• PWH is funded by the Bill & Melinda Gates Foundation, the Wellcome Trust,
and the UK Department of Health and Social Care. This work was also
supported by China Evergrande Group, Jack Ma Foundation, Sino
Biopharmaceutical Limited, Ping An Insurance (Group) and New Sunshine
Charity Foundation.
The study funders had no role in the study design; collection, management,
analysis, or interpretation of data; writing of the report; or the decision to
submit the report for publication.
Availability of data and materials {29}
The datasets generated during and/or analysed during the current study will
be made available.
Ethics approval and consent to participate {24}
This trial has been approved by the ethical review board of the China-Japan
Friendship Hospital, No. 2, East Yinghua Road, Chaoyang District, Beijing,
100029, China.
Informed consent will be obtained from all study participants.
Consent for publication {32}
Not applicable.
Competing interests {28}
The authors declare that they have no competing interests.
Author details
1Department of Pulmonary and Critical Care Medicine, Center of Respiratory
Medicine, National Clinical Research Center for Respiratory Diseases,
China-Japan Friendship Hospital, Beijing, China. 2Jin Yin-tan Hospital, Wuhan,
Hubei Province, China. 3Tongji Hospital, Tongji Medical College of Huazhong
University of Science & Technology, Wuhan, China. 4Wuhan Lung Hospital,
Wuhan, China. 5The Central Hospital of Wuhan, Wuhan, China. 6Zhongnan
Hospital of Wuhan University, Wuhan, China. 7Renmin Hospital of Wuhan
University, Wuhan, China. 8Union Hospital, Tongji Medical College of
Huazhong University of Science & Technology, Wuhan, China. 9Wuhan First
Hospital, Wuhan, China. 10Wuhan Third Hospital, Wuhan, China. 11Wuhan
Fourth Hospital, Wuhan, China. 12Institute of Medicine, Chinese Academy of
Medical Sciences, Beijing, China. 13Institute of Clinical Medical Sciences,
China-Japan Friendship Hospital, Beijing, China. 14Lancaster University,
Lancaster, UK. 15University of Virginia School of Medicine, Charlottesville, VA,
USA. 16ISARIC, University of Oxford, Oxford, UK. 17Institute of Respiratory
Medicine, Chinese Academy of Medical Sciences, Beijing, China. 18Peking
Union Medical College, Beijing, China.
Received: 18 February 2020 Accepted: 27 April 2020
References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics
of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
descriptive study. Lancet. 2020;395:507–13.
4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized
patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
JAMA. 2020. https://doi.org/10.1001/jama.2020.1585.
5. Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog
inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep. 2017;7:43395.
6. WHO. WHO R&D blueprint: informal consultation on prioritization of
candidate therapeutic agents for use in novel coronavirus 2019 infection.
Geneva: WHO; 2020.
7. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule
GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–
5.
8. Jordan PC, Liu C, Raynaud P, et al. Initiation, extension, and termination of
RNA synthesis by a paramyxovirus polymerase. PLoS Pathog. 2018;14(2):
e1006889.
9. Tchesnokov EP, Feng JY, Porter DP, Gotte M. Mechanism of inhibition of
Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;
11(4):E326.
10. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734
inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;
9(396):eaal3653.
11. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell
Res. 2020;30(3):269–71.
12. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir
inhibits human endemic and zoonotic deltacoronaviruses with a highly
divergent RNA dependent RNA polymerase. Antivir Res. 2019;169:104541.
13. de Wit E, Feldmann F, Cronina J, et al. Prophylactic and therapeutic
remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV
infection. Proc Natl Acad Sci U S A. 2020;117(12):6771–6.
14. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of
remdesivir and combination lopinavir, ritonavir, and interferon beta against
MERS-CoV. Nat Commun. 2020;11(1):222.
15. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of
Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303.
16. Whitehead J, Stratton I. Group sequential clinical trials with triangular
continuation regions. Biometrics. 1983;39(1):227–36.
17. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. J Pharmacol
Pharmacother. 2010;1(2):100–7.
18. Dimairo M, Coates E, Pallmann P, et al. Development process of a
consensus-driven CONSORT extension for randomised trials using an
adaptive design. BMC Med. 2018;16(1):210.
19. Whitehead J. The design and analysis of sequential clinical trials. 2nd ed.
Chichester: Wiley; 1997.
20. World Health Organization. Ethics in epidemics, emergencies and disasters:
research, surveillance and patient care. 2015.
21. Saxena A, Horby P, Amuasi J, et al. Ethics preparedness: facilitating ethics
review during outbreaks - recommendations from an expert panel. BMC
Med Ethics. 2019;20(1):29.
22. Nuffield Council on Bioethics. Research in global health emergencies:
ethical issues, 2020.
23. US Department of Health and Human Services Food and Drug
Administration. Guidance for Industry. Influenza: developing drugs for
treatment and/or prophylaxis. 2011.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Wang et al. Trials          (2020) 21:422 Page 11 of 11
